Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement

Core Viewpoint - Inspira Technologies has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its ordinary shares have been trading below $1.00 for the last 30 consecutive business days [1][2]. Compliance and Trading Status - The notification does not immediately affect the listing or trading of the Company's ordinary shares, which will continue to trade under the symbol "IINN" on The Nasdaq Capital Market [2]. - The Company has a compliance period of 180 calendar days, until August 10, 2026, to regain compliance by ensuring the closing bid price is at least $1.00 for a minimum of ten consecutive business days [2][3]. Potential for Additional Compliance Period - If compliance is not regained by August 10, 2026, the Company may qualify for a second 180-calendar day compliance period, provided it meets other listing requirements and notifies Nasdaq of its intention to cure the deficiency [3]. Monitoring and Future Actions - The Company plans to monitor the closing bid price of its ordinary shares and will consider options to regain compliance within the compliance period [4]. Company Overview - Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring solutions, with FDA-cleared products including the INSPIRA™ ART100 system and the upcoming INSPIRA ART500 system [5]. - The Company is also developing the HYLA™ blood sensor platform for continuous, non-invasive monitoring, positioning itself as a significant player in the life-support and MedTech sectors [5].